An Overview of Gene Therapy and Editing and the Differences between Them
DOI:
https://doi.org/10.58445/rars.324Keywords:
Genetics, Gene Therapy, Gene Editing, Biology, CRISPR, CRISPR-Cas9Abstract
This review paper provides an overview of gene therapy and gene editing, highlighting their differences, methodologies, historical developments, and ethical considerations. Gene therapy involves the use of viral vectors to introduce therapeutic copies of genes, while gene editing utilizes tools like CRISPR-Cas9 to modify existing genes. This paper explores the history of these approaches and their potential for treating genetic diseases. Ethical considerations in gene therapy and gene editing, including informed consent, safety, equity, and societal implications, are discussed.
References
Lundstrom, K. (2018). Viral Vectors in Gene Therapy. Diseases, 6(2), 42.
https://doi.org/10.3390/diseases6020042
Redman, M., King, A. J., Watson, C., & King, D. A. (2016). What is CRISPR/Cas9? Archives of Disease in Childhood-education and Practice Edition, 101(4), 213–215. https://doi.org/10.1136/archdischild-2016-310459
Ghosh, S., Brown, A., Jenkins, C., & Campbell, K. M. (2020). Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Applied Biosafety, 25(1), 7–18. https://doi.org/10.1177/1535676019899502
Viral Vector and gene therapy basics summarized. (2021, June 24). Biovian. https://biovian.com/news/viral-vector-and-gene-therapy-basics-summarized/
Shieh, W. (2022). Human adenovirus infections in pediatric population - An update on clinico–pathologic correlation. Biomedical Journal, 45(1), 38–49. https://doi.org/10.1016/j.bj.2021.08.009
McConnell, M. V., & Imperiale, M. J. (2004). Biology of Adenovirus and Its Use as a Vector for Gene Therapy. Human Gene Therapy, 15(11), 1022–1033. https://doi.org/10.1089/hum.2004.15.1022
Thacker, E. E., Timares, L., & Matthews, Q. L. (2009). Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Review of Vaccines, 8(6), 761–777. https://doi.org/10.1586/erv.09.29
American Society for Microbiology. (n.d.). Gene Therapy Using Adeno-Associated Virus Vectors | Clinical Microbiology Reviews. Clinical Microbiology Reviews. https://journals.asm.org/doi/10.1128/cmr.00008-08
McClements, M. E. (2017, December 1). Focus: Genome Editing: Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes. PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733846/
Croze, R. H., Kotterman, M. A., Burns, C., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2020). Viral Vector Technologies and Strategies: Improving on Nature. International Ophthalmology Clinics, 61(3), 59–89. https://doi.org/10.1097/iio.0000000000000361
Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2011). Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance. Scientifica, 2012, 1–14. https://doi.org/10.6064/2012/694137
Lana, M. G., & Strauss, B. E. (2019). Production of Lentivirus for the Establishment of CAR-T Cells. Methods in Molecular Biology, 61–67. https://doi.org/10.1007/978-1-0716-0146-4_4
Schlimgen, R., Howard, J., Wooley, D. P., Thompson, M., Baden, L. R., Yang, O. O., Christiani, D. C., Mostoslavsky, G., Diamond, D. V., Duane, E. G., Byers, K. B., Winters, T., Gelfand, J. A., Fujimoto, G., Hudson, T., & Vyas, J. M. (2016). Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. Journal of Occupational and Environmental Medicine, 58(12), 1159–1166. https://doi.org/10.1097/jom.0000000000000879
Tamura, R., & Toda, M. (2019). Historic Overview of Genetic Engineering Technologies for Human Gene Therapy. Neurologia Medico-chirurgica, 60(10), 483–491. https://doi.org/10.2176/nmc.ra.2020-0049
Marshall, E. (1999). Gene Therapy Death Prompts Review of Adenovirus Vector. Science, 286(5448), 2244–2245. https://doi.org/10.1126/science.286.5448.2244
Kumar, S., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2015). Clinical development of gene therapy: results and lessons from recent successes. Molecular Therapy. Methods & Clinical Development, 3, 16034. https://doi.org/10.1038/mtm.2016.34
Santa Clara University. (n.d.). Justice and Fairness. Markkula Center for Applied Ethics. https://www.scu.edu/ethics/ethics-resources/ethical-decision-making/justice-and-fairness/
Ma, Y., Zhang, L., & Huang, X. (2014). Genome modification by CRISPR/Cas9. FEBS Journal, 281(23), 5186–5193. https://doi.org/10.1111/febs.13110
MRS Bulletin , Volume 41 , Issue 11: Metal–Organic Frameworks for Electronics and Photonics , November 2016 , pp. 832 - 835 https://doi.org/10.1557/mrs.2016.250
Maguin, P., & Marraffini, L. A. (2021). From the discovery of DNA to current tools for DNA editing. Journal of Experimental Medicine, 218(4). https://doi.org/10.1084/jem.20201791
What Is Sickle Cell Disease? | NHLBI, NIH. (2022, July 22). NHLBI, NIH. https://www.nhlbi.nih.gov/health/sickle-cell-disease
Frangoul, H., & Davies, K. (2023). Opening a Crack in the Door: An Interview with Haydar Frangoul. GEN Biotechnology, 2(1), 16–20. https://doi.org/10.1089/genbio.2023.29082.hfr
Stein, R. (2020, June 23). A Year In, 1st Patient To Get Gene Editing For Sickle Cell Disease Is Thriving. NPR. https://www.npr.org/sections/health-shots/2020/06/23/877543610/a-year-in-1st-patient-to-get-gene-editing-for-sickle-cell-disease-is-thriving
Rafii, S., Tashkandi, E., Bukhari, N., & Al-Shamsi, H. O. (2022). Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges. Cancers, 14(4), 947. https://doi.org/10.3390/cancers14040947
Gene-editing summit touts sickle cell success, while questions on embryo editing linger. (2023, August 7). Science | AAAS. https://www.science.org/content/article/gene-editing-summit-touts-sickle-cell-success-while-questions-embryo-editing-linger
Posted
Categories
License
Copyright (c) 2023 Eusha Rahman
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.